TY  - INPR
A1  - Schultz, Bruce
A1  - Zaliani, Andrea
A1  - Ebeling, Christian
A1  - Reinshagen, Jeanette
A1  - Bojkova, Denisa
A1  - Lage-Rupprecht, Vanessa
A1  - Karki, Reagon
A1  - Lukassen, Sören
A1  - Gadiya, Yojana
A1  - Ravindra, Neal G.
A1  - Das, Sayoni
A1  - Baksi, Shounak
A1  - Domingo Fernández, Daniel
A1  - Lentzen, Manuel
A1  - Strivens, Mark
A1  - Raschka, Tamara
A1  - Cinatl, Jindrich
A1  - DeLong, Lauren Nicole
A1  - Gribbon, Phil
A1  - Geisslinger, Gerd
A1  - Ciesek, Sandra
A1  - Dijk, David van
A1  - Gardner, Steve
A1  - Tom Kodamullil, Alpha
A1  - Fröhlich, Holger
A1  - Peitsch, Manuel
A1  - Jacobs, Marc
A1  - Hoeng, Julia
A1  - Eils, Roland
A1  - Claussen, Carsten
A1  - Hofmann-Apitius, Martin
T1  - The COVID-19 PHARMACOME: a method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization
T2  - bioRxiv
N2  - The SARS-CoV-2 pandemic has challenged researchers at a global scale. The scientific community’s massive response has resulted in a flood of experiments, analyses, hypotheses, and publications, especially in the field of drug repurposing. However, many of the proposed therapeutic compounds obtained from SARS-CoV-2 specific assays are not in agreement and thus demonstrate the need for a singular source of COVID-19 related information from which a rational selection of drug repurposing candidates can be made. In this paper, we present the COVID-19 PHARMACOME, a comprehensive drug-target-mechanism graph generated from a compilation of 10 separate disease maps and sources of experimental data focused on SARS-CoV-2 / COVID-19 pathophysiology. By applying our systematic approach, we were able to predict the synergistic effect of specific drug pairs, such as Remdesivir and Thioguanosine or Nelfinavir and Raloxifene, on SARS-CoV-2 infection. Experimental validation of our results demonstrate that our graph can be used to not only explore the involved mechanistic pathways, but also to identify novel combinations of drug repurposing candidates.
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/72863
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-728632
IS  - 2020.09.23.308239
ER  -